NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center